<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03790592</url>
  </required_header>
  <id_info>
    <org_study_id>LISA tri 839MP BER-401-18</org_study_id>
    <nct_id>NCT03790592</nct_id>
  </id_info>
  <brief_title>Visual Outcomes After Presbyopic Lens Exchange</brief_title>
  <acronym>RELAX</acronym>
  <official_title>Visual Outcomes and Patient Satisfaction After Presbyopic Lens Exchange With a Trifocal Intraocular Lens (IOL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of mean preoperative and postoperative Corrected distance visual acuity (CDVA)
      after Refractive Lens Exchange in presbyopic patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compare preoperative and postoperative Corrected distance visual acuity
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Actual">December 9, 2019</completion_date>
  <primary_completion_date type="Actual">December 9, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected distance visual acuity</measure>
    <time_frame>4 to 6 months postop</time_frame>
    <description>preoperative and postoperative Corrected distance visual acuity will be assessed</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>trifocal IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients implanted with a trifocal intraocular lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>trifocal IOL</intervention_name>
    <description>intraocular lens</description>
    <arm_group_label>trifocal IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient informed of the consequences and constraints of the protocol and who has given
             his/her written informed consent

          2. Patients of any gender, aged 18 years or older

          3. Assured follow-up examinations

          4. Post-operative astigmatism â‰¤ 0.75 Diopter

          5. IOL implanted into the capsular bag with trifocal IOL in both eyes

          6. Patients who had bilateral uncomplicated presbyopic lens exchange surgery in both
             healthy eyes

          7. Preoperative monocular and binocular CDVA equal or better than 0.2 logMAR

          8. Normal findings in the medical history and physical examination

        Exclusion Criteria:

          1. Patients unable to meet the limitations of the protocol or likely of non-cooperation
             during the trial

          2. Patients whose freedom is impaired by administrative or legal order

          3. Concurrent participation in another drug or device investigation that affects patients
             vision

          4. Signs of early cataract in either eye

          5. Preoperative monocular and binocular CDVA worse than 0.2 logMAR

          6. Clinically significant Posterior capsule opacification (PCO) defined as a CDVA loss of
             0.2 logMAR or more in either eye

          7. Cataract of any grade

          8. Ocular disorders, that could potentially cause future acuity loss to a level of 0.20
             logMAR (best-corrected) or worse in either eye

          9. Any anterior segment pathology that could significantly affect outcomes (e.g. chronic
             uveitis, iritis, aniridia, rubeosis iridis, clinically significant anterior membrane
             dystrophies, poor pupil dilation, etc.)

         10. Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal
             degeneration, or irregular astigmatism, clinically significant corneal membrane
             dystrophies)

         11. Any condition in the study eye that could affect IOL stability (e.g. zonular dialysis,
             evident zonular weakness or dehiscence, etc.)

         12. History of any clinically significant retinal pathology or ocular diagnosis (e.g.
             diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment,
             optic neuropathy optic nerv atrophy, amblyopia, strabismus, microphthalmos, aniridia,
             epiretinal membrane etc.) in the study eyes that could alter or limit final
             postoperative visual prognosis.

         13. Patients, who are unable to fixate for a longer time, e.g. strabismus, nystagmus

         14. Patient expected to require retinal laser treatment before 6 month follow-up visit

         15. Patient require refractive laser treatment / refractive laser touch-up before 6 month
             follow up visit

         16. Current Systemic or ocular pharmacotherapy that effects patients vision

         17. Floppy iris syndrome

         18. Monophthalmic patient

         19. Previous corneal surgery

         20. Previous use of cytotoxic drugs or total body irradiation

         21. Dementia

         22. Uncontrolled glaucoma or Intraocular pressure (IOP) higher than 24 millimeter of
             mercury (mmHg) under ocular hypertension treatment

         23. Any other pathology or condition presenting, according to the investigator opinion, a
             risk for the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Augenzentrum Michelfeld</name>
      <address>
        <city>Michelfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 28, 2018</study_first_submitted>
  <study_first_submitted_qc>December 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2018</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

